Skip to content
AnalystLens

AbbVie Inc. 8-K Report, Regulation FD Disclosure (Jun 22, 2026)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed June 22, 2026
Period End
June 18, 2026
Security
ABBV
In the record · 2016–202610-K1110-Q328-K163

ABBV filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 163 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’16Nov ’16
  2. Impairment8-K · Jan ’19Jan ’19
  3. Leadership change8-K · Jan ’21Jan ’21
  4. Leadership change8-K · May ’25May ’25

01—Abstract

Summary

Summary of the 8-K filed June 22, 2026. Cited figures are marked; the original filing is the authoritative source.

AbbVie (NYSE: ABBV) has agreed to acquire Apogee Therapeutics (NASDAQ: APGE) for $135.11a per share in cash, a total equity value of approximately $10.9 billion, or about $10.1 billion net of estimated cash and marketable securities acquired.

The offer represents a premium of roughly 49%b to Apogee's June 18, 2026 closing price. The boards of both companies have unanimously approved the transaction, which is expected to close in the third quarter of 2026, subject to Apogee shareholder approval, regulatory clearances, and other customary conditions. Fairmount Funds and Venrock Associates have already signed voting agreements supporting the deal.

The strategic rationale centers on Apogee's lead asset, zumilokibart (APG777), a half-life extended anti-IL-13 antibody in Phase 3-ready development for atopic dermatitis (AD). AbbVie reports positive Phase 2 APEX data, with roughly two-thirds of patients achieving significant skin clearance at 16 weeks, and points to dosing of every 12 or 24 weeks as a convenience differentiator. Phase 3 AD trials are expected to start in the second half of 2026, with potential approval around early 2030.

Apogee's broader pipeline, including APG273 (IL-13 plus TSLP combination) in asthma and COPD, extends AbbVie into large respiratory markets. Management characterizes the pipeline as having mega-blockbuster peak sales potential, though the APG273 asset is ascribed modest value given its early stage. Financially, AbbVie will fund the acquisition with debt and expects a negative impact to adjusted diluted EPS of about $0.14c in 2026 and $0.46 in 2027, with accretion beginning in 2032.

Management states there is no change to capital allocation priorities, the dividend remains a commitment, and the company expects to maintain its A2/A- credit ratings while targeting 2xd net leverage within 2-3 years of closing. The filing is a Regulation FD disclosure, and the forward-looking statements and the risk of clinical, regulatory, and deal-completion failure should be weighed alongside these projections.

02—Key points

Key Highlights

  1. Acquisition price of $135.11 per Apogee share in cash, implying ~$10.9B total equity value (~$10.1B net of acquired cash and securities) and a ~49% premium to the June 18, 2026 close.
  2. Lead asset zumilokibart (APG777), an extended half-life anti-IL-13 antibody, is in Phase 3-ready development for atopic dermatitis, with Phase 3 starting 2H26 and potential approval around early 2030.
  3. Apogee's pipeline adds asthma and COPD exposure via APG273 (IL-13 + TSLP combination), with clinical trial plans to be announced in 2H26; AbbVie assigns modest value to this early-stage asset.
  4. Deal to be funded with debt; expected adjusted diluted EPS dilution of ~$0.14 in 2026 and ~$0.46 in 2027, with accretion beginning in 2032.
  5. AbbVie expects to maintain A2/A- credit ratings and targets 2x net leverage within 2-3 years of closing, with no change to capital allocation priorities or dividend commitment.
  6. Closing expected in Q3 2026, subject to Apogee shareholder approval, regulatory approvals, and customary conditions; voting agreements from Fairmount Funds and Venrock Associates support the deal.
  7. Efficacy comparisons versus marketed AD biologics are cross-trial, not head-to-head, and AbbVie notes zumilokibart has not been approved, so claimed differentiation remains unproven.

03—Questions

Frequently Asked Questions

  1. How much is AbbVie paying for Apogee and what premium does that represent?

    AbbVie is paying $135.11 per share in cash, a total equity value of approximately $10.9 billion. That is about $10.1 billion net of estimated cash and marketable securities acquired, and represents a premium of roughly 49% to Apogee's closing price on June 18, 2026.

  2. What is the main asset AbbVie is acquiring, and when could it reach the market?

    The core asset is zumilokibart (APG777), a half-life extended anti-IL-13 antibody being developed in atopic dermatitis. Phase 3 AD trials are expected to begin in 2H 2026, with potential approval in early 2030, so commercial revenue would not arrive for several years.

  3. How will the acquisition affect AbbVie's earnings and balance sheet?

    AbbVie expects the deal to reduce adjusted diluted EPS by about $0.14 in 2026 and $0.46 in 2027, with accretion starting in 2032. The company will fund it with debt, aims to keep its A2/A- ratings, and targets 2x net leverage within 2-3 years of closing.

  4. What could prevent or delay the deal from closing?

    Closing requires Apogee shareholder approval and regulatory clearances, and is expected in Q3 2026. The filing also flags risks including termination fee triggers, competing acquisition proposals, litigation, and disruption to business operations, though voting agreements from Fairmount Funds and Venrock Associates support the transaction.

  5. Are the efficacy claims for zumilokibart directly comparable to existing AD treatments?

    Not directly. The presentation's comparisons to Ebglyss, Dupixent, and Nemluvio are cross-trial, not head-to-head, and AbbVie acknowledges differences in trial design and populations. Investors should treat claims of best-in-category efficacy as unproven until later-stage data are available.

04—Continue

← View all 8-K filings